We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CV drug

News List

Novartis exercises rights to Ionis’ CV drug TQJ230 pharmaceutical-technology
February 26, 2019
Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy....
Copay coupons help (a little) with CV drug adherence but not outcomes fiercepharma
January 17, 2019
Copay coupons have long been a contentious topic in pharma, as critics have blasted the promo strategy for driving up drug costs.
Copay coupons help (a little) with CV drug adherence but not outcomes fiercepharma
January 17, 2019
Copay coupons have long been a contentious topic in pharma, as critics have blasted the promo strategy for driving up drug costs.